Odds are extremely high, especially early in the pandemic & production ramp up of LLmab, that Aviptadil will be used for patients presenting strictly pulmonary issues, while LLmab gets used as patients progress from moderate to severe and show elevated cytokines / depressed T cells.

LLmab will be in high demand for at least a year for CV alone, even after the first wave and herd immunity starts to get established, as a prophylactic for doctors, nurses, Frontline workers, etc. Plenty of room for both. But Aviptadil doesn't have the other indications we all know LLmab shows promise in.